Related Experiment Video
Updated: Jun 13, 2025
Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
SIRT1-FOXOs signaling pathway: A potential target for attenuating cardiomyopathy
Changxu Lu1, Can Gao1, Jinwen Wei1
1College of Exercise and Health, Shenyang Sport University, Shenyang, Liaoning, China.
Insights
Sirtuin 1 (SIRT1) and Forkhead O transcription factors (FOXOs) protect against cardiomyocyte loss, a key factor in cardiomyopathy. This SIRT1-FOXO pathway offers potential for new cardiomyopathy treatments.
Area of Science:
- Cardiovascular Biology
- Molecular Mechanisms of Disease
- Biochemistry
Background:
- Cardiomyopathy is a significant global health issue leading to heart failure, with no definitive treatments currently available.
- Existing therapies focus on symptom management rather than addressing the root causes, such as cardiomyocyte loss.
- Cardiomyocyte loss, driven by factors like metabolic issues, stress, and apoptosis, is a critical risk factor for cardiomyopathy progression.
Purpose of the Study:
- To elucidate the fundamental mechanism by which Sirtuin 1 (SIRT1) and Forkhead O transcription factors (FOXOs) inhibit cardiomyocyte loss.
- To review the regulatory factors influencing the SIRT1-FOXO signaling pathway in the context of cardiomyopathy.
- To explore the potential clinical applications of the SIRT1-FOXO pathway in developing novel cardiomyopathy treatments.
Main Methods:
- Review of existing scientific literature on Sirtuin 1 (SIRT1), Forkhead O transcription factors (FOXOs), and cardiomyopathy.
- Analysis of the molecular signaling pathway involving SIRT1 and FOXOs in myocardial tissue.
- Summary of regulatory factors and potential therapeutic targets within the SIRT1-FOXO pathway.
Main Results:
- The SIRT1-FOXO signaling pathway plays a crucial role in preventing cardiomyocyte loss.
- SIRT1, a class III histone deacetylase, influences FOXOs, its downstream effectors, in regulating cell survival.
- Understanding this pathway provides insights into mitigating myocardial injury.
Conclusions:
- The SIRT1-FOXO pathway is a key protective mechanism against cardiomyocyte loss in cardiomyopathy.
- Further research into SIRT1-FOXO regulation could lead to innovative therapeutic strategies for cardiomyopathy.
- Targeting the SIRT1-FOXO pathway holds promise for future clinical interventions in heart failure treatment.
Abstract:
Cardiomyopathy constitutes a global health burden. It refers to myocardial injury that causes alterations in cardiac structure and function, ultimately leading to heart failure. Currently, there is no definitive treatment for cardiomyopathy. This is because existing treatments primarily focus on drug interventions to attenuate symptoms rather than addressing the underlying causes of the disease. Notably, the cardiomyocyte loss is one of the key risk factors for cardiomyopathy. This loss can occur through various mechanisms such as metabolic disturbances, cardiac stress (e.g., oxidative stress), apoptosis as well as cell death resulting from disorders in autophagic flux, etc. Sirtuins (SIRTs) are categorized as class III histone deacetylases, with their enzyme activity primarily reliant on the substrate nicotinamide adenine dinucleotide (NAD (+)). Among them, Sirtuin 1 (SIRT1) is the most intensively studied in the cardiovascular system. Forkhead O transcription factors (FOXOs) are the downstream effectors of SIRT1. Several reports have shown that SIRT1 can form a signaling pathway with FOXOs in myocardial tissue, and this pathway plays a key regulatory role in cell loss. Thus, this review describes the basic mechanism of SIRT1-FOXOs in inhibiting cardiomyocyte loss and its favorable role in cardiomyopathy. Additionally, we summarized the SIRT1-FOXOs related regulation factor and prospects the SIRT1-FOXOs potential clinical application, which provide reference for the development of cardiomyopathy treatment.
